U.S. states sue Mylan, Teva, others for fixing drug prices
None
WASHINGTON - Twenty states filed a lawsuit Thursday against Mylan NV, Teva Pharmaceuticals and four other generic drug makers, saying they conspired on pricing of two common generic drugs, according to a copy of the complaint.
The civil lawsuit is one piece of a broader generic drug pricing probe that remains under way at the state and federal level, as well as in the U.S. Congress. The inquiries have grown over the past two years to include multiple drugs and companies, some of which have disclosed they are being investigated by the Justice Department.
The drugs involved in Thursday's lawsuit include the delayed release version of a common antibiotic, doxycycline hyclate; and glyburide, an older drug used to treat diabetes.
The lawsuit, filed in the U.S. District Court for the District of Connecticut, names Heritage Pharmaceuticals Inc as a "ring leader" of the price manipulation, and also lists Mayne Pharma, Aurobindo Pharma and Citron Pharma LLC as participants.
